Monica Rivera Beam

ENTREPRENEURSHIP EDUCATION CAREER DEVELOPMENT The California Life Science Institute's mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI entrepreneurship programs connect startups with the resources and expertise needed to sustain critical innovation in the industry. CLSI provides unique offerings to CLSA’s Fellow startup members, including educational workshops, research database access, and peer and executive networking. Fellow entrepreneurs can also access expertise from business advisors through CLSI’s Expert Network, and more intensive coaching through the FAST Advisory Program (http://califesciencesinstitute.org/entrepreneurship/fast-advisory-program/). CLSI is also a member of CARB-X, an international accelerator program focused on supporting antibiotic product development over the next 25 years (http://califesciencesinstitute.org/entrepreneurship/carb-x/).

TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company’s Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Our lead program TRB-061, currently in a Ph1 clinical trial for atopic dermatitis, is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California. For more info, visit www.trex.bio.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.

At DICE, we are expecting more out of medicine. We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. Through combining innovative chemistry with well-validated biology, our goal is to make medicines more accessible and unlock the potential of oral medicines. Our team is led by an exceptional group of scientists, R&D executives and company builders with demonstrated track records of progressing programs from discovery through regulatory approval and commercialization. Together, we’re building a team that has a passion for innovation and extensive experience in small molecule drug discovery and development.

We are a vibrant young company committed to science first. Our mission is to develop and deliver the unprecedented accuracy of TwinStrand Duplex Sequencing® technology for applications in clinical medicine and life sciences where it can do the greatest good for the greatest number of people. Our approach is multifaceted and encompasses internal development projects, external collaborations and empowering of partner organizations. TwinStrand Duplex Sequencing® technology is an ultra-high accuracy, error-corrected sequencing method that overcomes the limitations of NGS by independently tracking both strands of individual DNA molecules. Utilizing our multi-patented novel chemistry and cloud-based bioinformatics, the paired sequences are compared to eliminate errors, reducing error rates from 1-in-100 to 1-in-10 million, revealing ultra-low frequency variants.

ENTREPRENEURSHIP EDUCATION CAREER DEVELOPMENT The California Life Science Institute's mission is to maintain California’s leadership in life sciences innovation through support of entrepreneurship, education and career development. CLSI entrepreneurship programs connect startups with the resources and expertise needed to sustain critical innovation in the industry. CLSI provides unique offerings to CLSA’s Fellow startup members, including educational workshops, research database access, and peer and executive networking. Fellow entrepreneurs can also access expertise from business advisors through CLSI’s Expert Network, and more intensive coaching through the FAST Advisory Program (http://califesciencesinstitute.org/entrepreneurship/fast-advisory-program/). CLSI is also a member of CARB-X, an international accelerator program focused on supporting antibiotic product development over the next 25 years (http://califesciencesinstitute.org/entrepreneurship/carb-x/).

TRexBio is a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology by leveraging cutting-edge computational biology tools, a focus on human tissue, and deep immunobiology expertise. The company’s Deep Biology platform maps human tissue Treg behavior to disease processes to identify and characterize novel targets for therapeutic intervention. Our lead program TRB-061, currently in a Ph1 clinical trial for atopic dermatitis, is a novel TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRexBio is headquartered in South San Francisco, California. For more info, visit www.trex.bio.

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molecule therapeutics against challenging, high-value drug targets.

At DICE, we are expecting more out of medicine. We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. Through combining innovative chemistry with well-validated biology, our goal is to make medicines more accessible and unlock the potential of oral medicines. Our team is led by an exceptional group of scientists, R&D executives and company builders with demonstrated track records of progressing programs from discovery through regulatory approval and commercialization. Together, we’re building a team that has a passion for innovation and extensive experience in small molecule drug discovery and development.